PI
BLUE

PEAK6 Investments’s bluebird bio BLUE Stock Holding History

PEAK6 Investments’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,702
Closed -$1.12M – 5178
2021
Q2 		$1.12M Hold
2,702
– – ﹤0.01% 2468
2021
Q1 		$1.05M Buy
2,702
+2,687
+17,913% +$1.32M ﹤0.01% 2489
2020
Q4 		$9K Sell
15
-294
-95% -$186K ﹤0.01% 4405
2020
Q3 		$216K Sell
309
-1,745
-85% -$1.36M ﹤0.01% 3454
2020
Q2 		$1.62M Sell
2,054
-3,165
-61% -$2.39M 0.01% 1667
2020
Q1 		$3.11M Sell
5,219
-1,204
-19% -$1.17M 0.02% 763
2019
Q4 		$7.3M Buy
6,423
+5,196
+423% +$5.65M 0.04% 478
2019
Q3 		$1.46M Hold
1,227
– – 0.01% 1483
2019
Q2 		$2.02M Buy
1,227
+115
+10% +$199K 0.01% 1272
2019
Q1 		$2.27M Buy
1,112
+178
+19% +$313K 0.01% 1217
2018
Q4 		$1.2M Hold
934
– – 0.01% 1618
2018
Q3 		$1.77M Buy
+934
New +$1.93M 0.01% 1521

Other funds holding BLUE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PEAK6 Investments's BLUE Position: Q3 2022 in Review

PEAK6 Investments sold out of bluebird bio (BLUE) in Q3 2022, closing a stake of 500 shares — an estimated $56.6K sold.

PEAK6 Investments first reported a position in BLUE in Q4 2018 and held it in 10 quarters. The position peaked at $2.48M in Q1 2020. 162 funds tracked by Wall St. Rank hold BLUE as of Q3 2022.

  • PEAK6 Investments reported no remaining bluebird bio position as of Q3 2022 after selling out during the quarter.
  • PEAK6 Investments sold 500 bluebird bio shares in Q3 2022, an estimated $56.6K.
  • PEAK6 Investments first reported a position in bluebird bio in Q4 2018 and held it in 10 quarters.
  • PEAK6 Investments's bluebird bio position peaked at $2.48M in Q1 2020.
  • 162 funds tracked by Wall St. Rank held bluebird bio as of Q3 2022.

Based on PEAK6 Investments's 13F filing for Q3 2022, filed 14 Nov 2022.